Navigation Links
Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis

NittoPhase® HL Loaded up to 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields

Oceanside, CA (PRWEB) April 26, 2010 -- Kinovate Life Sciences, Inc., a California based subsidiary of Nitto Denko Corporation, and the market leader in solid support for oligonucleotide synthesis, will be launching its next generation high loading polymeric solid support product NittoPhase®HL for oligonucleotide synthesis at the TIDES meeting commencing in Boston on April 26th. In thorough testing, NittoPhase®HL loaded at 350umol/g and 250umol/g has shown consistently strong yields and excellent full length purity when utilized for DNA and RNA synthesis respectively. The product will also be commercialized loaded both with succinate and Universal Linker at various levels up to 400umol/g for various applications. Custom loadings included various modified linkers and loading levels will also be available. Kinovate will still continue to sell its market leading original NittoPhase® product.

Utilizing the unparalleled polymer synthesis and R&D capabilities of Nitto Denko Corporation, and the worldwide marketing operations of Kinovate Life Sciences, this new product promises to deliver significantly improved technical and economic outcomes for all segments of the oligonucleotide industry.

Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides. The market leading loading capacity of NittoPhase®HL results in significantly improved yields per gram of material with superior purity, allowing users to realize significant cost savings with no compromise in quality.

“NittoPhase®HL truly represents a quantum leap in solid support technology for oligonucleotide synthesis. No other support on the market offers these extremely high loadings, together with consistently robust yields and purities. The increase in synthesis scale per gram of support will result in significant reductions in the per micromole costs of oligonucleotide manufacture; not just directly related to the support, but also through the reduction in use of associated solvents and other reagents. Preliminary studies undertaken by an independent third party have shown a reduction in raw materials cost of 40%, equating with a 15% reduction in overall synthesis costs when using NittoPhase®HL.” stated Dr. Kenji Matsumoto, President of Kinovate Life Sciences, Inc.

Dr. Matsumoto added, “In particular, NittoPhase®HL represents a major breakthrough in the synthesis of RNAi drugs. Where previously Controlled Porous Glass (CPG) supports were dominant, NittoPhase®HL now offers a compelling alternative to overcome the technical limitations and costs of those products. Following on from the extraordinary success of our original NittoPhase® Solid Support product, which has fast become well established as the market leading solid support in the therapeutic oligonucleotide industry, NittoPhase®HL will cement Kinovate’s position as the market leader in this field.”

Manufacture of oligonucleotide drugs involves use of solid support matrix upon which chemical reactions occur in a cyclic manner. These reactions are performed on a fully automated synthesizer. At the end of synthesis, drugs are purified by various chromatographic techniques and characterized extensively to check their authenticity and purity. Thus solid support plays a crucial role in the manufacture of oligonucleotide drugs. It is increasingly believed that the yield of full-length oligonucleotide product is greatly influenced by the proper design of a polymeric support which undergoes roughly eighty chemical reactions in about eight hours for a 20-mer oligonucleotide.

Kinovate Life Sciences, Inc. is a subsidiary of Nitto Denko Corporation (Osaka, Japan). Whose mission is the commercialization and marketing of life science-related technologies developed by Nitto Denko Corporation and its Oceanside, CA based R&D subsidiary company Nitto Denko Technical Corporation. In April 2005, Kinovate launched NittoPhase® Solid Support for Oligonucleotide Synthesis, which has gone on to became the market leading product in its class.

Nitto Denko was founded in 1918 with its head office in Osaka, Japan. Fully utilizing its core technologies such as polymer synthesis, adhesion and coating technologies to add diverse functionality to sheets, films and other materials, Nitto Denko Group offers to the global market a wide range of high-value-added products including optical films for liquid crystal displays, automotive materials and parts, reverse osmosis membranes for seawater desalination, transdermal drug delivery patches, and much more. Additional information about Nitto Denko Corporation is available at

This press release contains forward looking statements concerning research & development of polymer materials related to the life sciences area developed and commercialized by Kinovate Life Sciences Inc. and its affiliates, including solid support for oligonucleotide synthesis. Any and all statements concerning Kinovate’s claims, intentions, beliefs, etc should be considered forward looking statements and as such at-risk. Statements made above, including those concerning testing results should be considered observed values, not guaranteed values, and actual results may differ materially from those mentioned above. Readers of this press release are cautioned to not rely solely on the forward-looking statements contained above.

Kinovate Life Sciences, Inc. is a wholly owned subsidiary of Nitto Denko Corporation.

For Kinovate Life Sciences:
Gaby Silver
Marketing Manager
Phone: +1-760-435-7042
Web :


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
2. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
3. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
4. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
5. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
6. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
7. Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology
8. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
9. Dow AgroSciences, Monsanto Complete U.S. and Canadian Regulatory Authorizations for SmartStax Corn; Plans Set to Launch Seed Platform on 3 Million- to 4 Million-Plus Acres
10. Derma Sciences, Inc. Hires the Investor Relations Group
11. Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology
Post Your Comments:
Related Image:
Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... FAR HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... University, as the recipient of the 2016 USGA Green Section Award. Presented annually since ... of golf through his or her work with turfgrass. , Clarke, of ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology:
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):